FindTrial
Sign In

Renal safety of analgesics in patients with Cardiovascular disease ; A descriptive study using a real world database

Renal safety of analgesics in patients with Cardiovascular disease ; A descriptive study using a real world database - Renal safety of analgesics in patients with Cardiovascular disease ; A descriptive study using a real world database

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000049086
Enrollment
Unknown
Registered
2022-10-03
Start date
2022-10-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

None listed

Sponsors

Kawaguchi Cardiovascular and Respiratory Hospita
Lead Sponsor
Kurashiki Central Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with heart failure (ICD-10 code: I50x) and BNP or NT-proBNP measurements

Exclusion criteria

Exclusion criteria: cancer, surgery, pregnancy

Design outcomes

Primary

MeasureTime frame
- Proportion of analgesics use in heart failure patients - Categories at baseline and sequential changes of renal function after administration of analgesics in patients with heart failure (eGFR or serum creatinine level)—

Secondary

MeasureTime frame
- Proportion and frequency of combination therapy other than analgesics (especially focusing on Triple Warmy Drugs) by category - For analgesics, proportion of concomitant use, daily and cumulative dose distribution, and proportion of single use - Distribution of registered comorbidities - Sequential changes of biomarker [index] in patients with heart failure from baseline (BNP or NT-proBNP) (BNP or NT-proBNP) - Incidence proportion of heart failure exacerbation events (hospitalization due to heart failure, administration of intravenous diuretics, and increased dose of oral diuretic)—

Countries

Japan

Contacts

Public ContactToshi Takano

AYUMI PHARMACEUTICAL CO., LTD Medical Affairs Div.

toshio.takano@ayumi-pharma.com0362643530

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026